SCH-50911 je selektivni antagonistGABAB[4]. On nalazi primenu u farmakološkim istraživanjima. Utvrđeno je da brzo i efektivno poništava simptome GHBpredoziranja kod miševa. U jednom eksperimentu, miševima su date letalne doze GHB-a (7000 mg/kg) i tome su sledile promenljive doze SCH-50911. Na dve najviše doze antagonista (150 mg/kg i 300 mg/kg), samo 2 od 20 miševa je uginulo (10%), u poređenju sa 100% letalnošću kontrolne grupe.[5]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Blythin DJ, Kuo SC, Shue HJ, McPhail AT, Chapman RW, Kreutner W, Rizzo C, She HS, West R. Substituted morpholine-2S-acetic acid derivatives: SCH 50911 and Related Compounds as Novel GABAB Antagonists. Bioorganic and Medicinal Chemistry Letters. 1996 Jul 9; 6(13): 1529-1534.
↑Carai MA, Colombo G, Gessa GL. Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice. Annals of Emergency Medicine 2005 Jun;45(6):614-9.